Clinical trial
A Phase II Study of Anecortave Acetate for the Treatment of Exudative…
NCT00346957 · Alcon Research, Industry · Completed
Key facts
| NCT number | NCT00346957 |
|---|---|
| Title | A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration |
| Lead sponsor | Alcon Research, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | AMD |
| Intervention type | Drug, Other |
| Interventions | Anecortave acetate 30 mg, Anecortave Acetate 15 mg, Anecortave Acetate 3 mg, Anecortave Acetate Vehicle |
| Enrollment | 128 |
| Start date | Apr 1, 1999 |
| Primary completion | Apr 1, 2003 |
| Completion | Apr 1, 2003 |
| First posted | Jul 4, 2006 |
| Last update posted | Mar 6, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: